Zymeworks (NYSE:ZYME) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.
According to Zacks, “Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada. “
Separately, Cormark reiterated a “buy” rating on shares of Zymeworks in a report on Saturday, September 30th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $14.35.
A hedge fund recently bought a new stake in Zymeworks stock. Franklin Resources Inc. purchased a new stake in Zymeworks Inc (NYSE:ZYME) in the 2nd quarter, according to its most recent filing with the SEC. The fund purchased 823,700 shares of the company’s stock, valued at approximately $6,878,000. Franklin Resources Inc. owned about 3.30% of Zymeworks as of its most recent filing with the SEC. 7.20% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Zymeworks (ZYME) Downgraded by Zacks Investment Research” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.com-unik.info/2018/01/13/zymeworks-zyme-downgraded-by-zacks-investment-research.html.
Zymeworks Company Profile
Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company’s ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company’s platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.